Search Results - "Bagameri, Andrea"

Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer by Vergote, Ignace, González-Martín, Antonio, Fujiwara, Keiichi, Kalbacher, Elsa, Bagaméri, Andrea, Ghamande, Sharad, Lee, Jung-Yun, Banerjee, Susana, Maluf, Fernando Cotait, Lorusso, Domenica, Yonemori, Kan, Van Nieuwenhuysen, Els, Manso, Luis, Woelber, Linn, Westermann, Anneke, Covens, Allan, Hasegawa, Kosei, Kim, Byoung-Gie, Raimondo, Miriam, Bjurberg, Maria, Cruz, Felipe Melo, Angelergues, Antoine, Cibula, David, Barraclough, Lisa, Oaknin, Ana, Gennigens, Christine, Nicacio, Leo, Teng, Melinda Siew Leng, Whalley, Elizabeth, Soumaoro, Ibrahima, Slomovitz, Brian M.

“…Recurrent cervical cancer has a poor prognosis. The median overall survival was nearly 1 year with tisotumab vedotin, an antibody–drug conjugate, as compared…”
Get full text

Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer by Olawaiye, Alexander B, Kim, Jae-Weon, Bagameri, Andrea, Bishop, Erin, Chudecka-Głaz, Anita, Devaux, Alix, Gladieff, Laurence, Gordinier, Mary E, Korach, Jacob, McCollum, Michael E, Mileshkin, Linda, Monk, Bradley J, Nicum, Shibani, Nogueira-Rodrigues, Angélica, Oaknin, Ana, O'Malley, David M, Orlando, Mauro, Dreiling, Lyndah, Tudor, Iulia C, Lorusso, Domenica

“…Ovarian cancer has the highest mortality among gynecologic cancers, primarily because it typically is diagnosed at a late stage and because of the development…”
Get full text

Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study by O'Malley, David M, Neffa, Maryna, Monk, Bradley J, Melkadze, Tamar, Huang, Marilyn, Kryzhanivska, Anna, Bulat, Iurie, Meniawy, Tarek M, Bagameri, Andrea, Wang, Edward W, Doger de Speville Uribe, Bernard, Hegg, Roberto, Ortuzar Feliu, Waldo, Ancukiewicz, Marek, Lugowska, Iwona

“…Balstilimab (antiprogrammed death-1) and zalifrelimab (anticytotoxic T-lymphocyte-associated antigen-4) are two new checkpoint inhibitors emerging as promising…”
Get full text

Does increasing the steroid dose enhance the efficacy of the antiemetic combination of granisetron and methylprednisolone in gynecologic cancer patients—a randomized study by Lehoczky, Ottó, Udvary, János, Bagaméri, Andrea, Pulay, Tamás

“…Objective: The authors administered two doses of oral methylprednisolone in combination with 3 mg granisetron intravenously for the prophylaxis of…”
Get full text

Efficacy and safety of tisotumab vedotin versus investigator's choice of chemotherapy in second-line or third-line recurrent or metastatic cervical cancer (innovaTV 301/ENGOT-cx12/GOG-3057): A global, randomized, open-label, phase III study by Slomovitz, Brian, González-Martín, Antonio, Fujiwara, Keiichi, Kalbacher, Elsa, Bagaméri, Andrea, Randall, Leslie, Lee, Jung-Yun, Banerjee, Susana, Maluf, Fernando, Lorusso, Domenica, Yonemori, Kan, Van Nieuwenhuysen, Els, Manso, Luis, Woelber, Linn, Westermann, Anneke, Covens, Allan, Whalley, Elizabeth, Chen, Yiyi, Soumaoro, Ibrahima, Vergote, Ignace

Get full text

Hypersensitivity reactions in paclitaxel treatment of ovarian cancer patients by Lehoczky, O., Bagaméri, Andrea, Udvary, J., Pulay, T.

“…Paclitaxel (PTXL) chemotherapy for treatment of epithelial ovarian cancers has become common worldwide since the 1990s. In early treatments severe allergic,…”
Get full text

Reinduction of paclitaxel therapy after a successfully treated hypersensitivity reaction by Lehoczky, Ottó, Bagaméri, Andrea, Pulay, Tamás

“…Paclitaxel containing chemotherapy is considered to be the first-line adjuvant treatment of epithelial ovarian cancers. Hypersensitive reaction is its most…”
Get more information

Results of docetaxel therapy in patients with relapsed ovarian cancer by Lehoczky, Ottó, Thurzó, László, Bagaméri, Andrea, Sárosi, Zsuzsanna, Udvary, János, Pulay, Tamás

“…Successful treatment of relapsed ovarian cancer has not been solved. Docetaxel, being one of the medicines of special interest in Hungary from 2002, has been…”
Get more information

Early results of topotecan therapy in patients with recurrent ovarian cancer by Lehoczky, Ottó, Bagaméri, Andrea, Lehoczky, Gyózó, Pulay, Tamás

“…Topotecan inhibits the topoisomerase-I enzyme resulting its stabilisation on the DNA and the suspension of replication and transcription. The authors…”
Get more information